Acurx Pharmaceuticals - ACXP Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACXP shares.
View ACXP analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12 month price objectives for Acurx Pharmaceuticals' shares. Their ACXP share price forecasts range from $14.00 to $14.00. On average, they anticipate the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 345.9% from the stock's current price.
View analysts price targets for ACXP or view top-rated stocks among Wall Street analysts.

Acurx Pharmaceuticals' stock was trading at $3.98 at the beginning of the year. Since then, ACXP shares have decreased by 21.1% and is now trading at $3.14.
View the best growth stocks for 2023 here.

Acurx Pharmaceuticals saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 24,900 shares, a drop of 33.8% from the February 13th total of 37,600 shares. Based on an average trading volume of 33,900 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.3% of the company's stock are sold short.
View Acurx Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our ACXP earnings forecast.

(ACXP) raised $15 million in an initial public offering on Friday, June 25th 2021. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities acted as the underwriters for the IPO.

Acurx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACXP."

Acurx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (7.59%), Millennium Management LLC (0.25%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia.
View institutional ownership trends.

Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACXP stock can currently be purchased for approximately $3.14.

Acurx Pharmaceuticals (NASDAQ:ACXP) has a market capitalization of $36.55 million. The company earns $-12,750,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

The official website for the company is www.acurxpharma.com. The company can be reached via phone at 917-533-1469 or via email at davidluci@acurxpharma.com.